|146.49||+3.68||+2.58%||Vol 412.96K||1Y Perf -19.84%|
|May 13th, 2022 16:00 DELAYED|
|-0.99 -0.68%||- -|
|Target Price||203.67||Analyst Rating||Strong Buy 1.33|
|Potential %||39.03||Finscreener Ranking||★★ 45.69|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★+ 44.71|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★ 38.35|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||40.43||Earnings Rating||Strong Buy|
|Market Cap||9.13B||Earnings Date||4th May 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||3.00|
|EPS Growth Next 5 Years %||8.20|
|Avg. Weekly Volume||625.23K|
|Avg. Monthly Volume||583.53K|
|Avg. Quarterly Volume||588.22K|
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) stock closed at 146.49 per share at the end of the most recent trading day (a 2.58% change compared to the prior day closing price) with a volume of 412.96K shares and market capitalization of 9.13B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1940 people. Jazz Pharmaceuticals plc CEO is Bruce C. Cozadd.
The one-year performance of Jazz Pharmaceuticals plc stock is -19.84%, while year-to-date (YTD) performance is 14.98%. JAZZ stock has a five-year performance of -4.75%. Its 52-week range is between 117.64 and 189, which gives JAZZ stock a 52-week price range ratio of 40.43%
Jazz Pharmaceuticals plc currently has a PE ratio of -20.40, a price-to-book (PB) ratio of 2.64, a price-to-sale (PS) ratio of 2.68, a price to cashflow ratio of 13.30, a PEG ratio of 2.32, a ROA of -4.96%, a ROC of -3.25% and a ROE of -12.51%. The company’s profit margin is -13.25%, its EBITDA margin is 22.40%, and its revenue ttm is $3.30 Billion , which makes it $52.96 revenue per share.
Of the last four earnings reports from Jazz Pharmaceuticals plc, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $3.00 for the next earnings report. Jazz Pharmaceuticals plc’s next earnings report date is -.
The consensus rating of Wall Street analysts for Jazz Pharmaceuticals plc is Strong Buy (1.33), with a target price of $203.67, which is +39.03% compared to the current price. The earnings rating for Jazz Pharmaceuticals plc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Jazz Pharmaceuticals plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Jazz Pharmaceuticals plc has a Sell technical analysis rating based on Technical Indicators (ADX : 9.56, ATR14 : 5.92, CCI20 : -96.81, Chaikin Money Flow : -0.07, MACD : -4.16, Money Flow Index : 8.61, ROC : -9.92, RSI : 37.14, STOCH (14,3) : 29.47, STOCH RSI : 0.94, UO : 40.04, Williams %R : -70.53), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Jazz Pharmaceuticals plc in the last 12-months were: Bruce C. Cozadd (Option Excercise at a value of $3 834 361), Bruce C. Cozadd (Sold 66 598 shares of value $9 500 614 ), Catherine A. Sohn (Sold 1 306 shares of value $193 236 ), Elmar Schnee (Sold 1 632 shares of value $251 328 ), Heather Ann McSharry (Sold 1 414 shares of value $209 215 ), Jennifer Cook (Sold 417 shares of value $50 582 ), Kenneth W. O'Keefe (Sold 1 306 shares of value $193 236 ), Kim Sablich (Sold 2 748 shares of value $371 000 ), Neena M. Patil (Sold 296 shares of value $45 559 ), Norbert G. Riedel (Sold 1 306 shares of value $193 236 ), Patricia Carr (Sold 314 shares of value $46 459 ), Paul L. Berns (Sold 1 450 shares of value $223 300 ), Peter P. Gray (Sold 1 414 shares of value $209 215 ), Rick E. Winningham (Sold 1 306 shares of value $193 236 )
Thu, 05 May 2022 12:27 GMT Jazz Pharmaceuticals (JAZZ) Gets a Buy Rating from Jefferies- TipRanks. All rights reserved.
Tue, 26 Apr 2022 12:38 GMT Jazz Pharmaceuticals (JAZZ) Gets a Buy Rating from Needham- TipRanks. All rights reserved.
Fri, 08 Apr 2022 01:47 GMT Jazz Pharmaceuticals (JAZZ) Gets a Buy Rating from RBC Capital- TipRanks. All rights reserved.
Thu, 07 Apr 2022 13:15 GMT Jazz Pharmaceuticals (JAZZ) Receives a Buy from Needham- TipRanks. All rights reserved.
Mon, 07 Feb 2022 11:16 GMT Jazz Pharmaceuticals (JAZZ) Received its Third Buy in a Row- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.